文献速递垂体与肾上腺疾病

巨大嗜铬细胞瘤患者的表现、管理与结局

Presentation, Management, and Outcomes of Patients With Giant Pheochromocytoma.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

这项回顾性队列研究在转诊中心2000至2023年开展,比较巨大嗜铬细胞瘤(≥10 cm)与非巨大嗜铬细胞瘤患者。巨大嗜铬细胞瘤患者症状更多、儿茶酚胺过量更严重、围术期并发症更高,转移率45% vs 4%,疾病特异性死亡率7% vs 0%。

要点

  • 巨大嗜铬细胞瘤患者儿茶酚胺过量症状中位数2 vs 参照组1(P = .04)。
  • 巨大嗜铬细胞瘤围术期并发症率31% vs 参照组10%(P = .004)。
  • 巨大嗜铬细胞瘤转移率45% vs 参照组4%(P < .0001),需密切随访。

核心结论

  • 与参照组相比,巨大嗜铬细胞瘤患者症状更多、儿茶酚胺过量程度更高、围术期并发症率更高。
  • 近半数巨大嗜铬细胞瘤患者发生转移, warranting close follow-up(需密切随访)。

研究设计与样本

  • 回顾性队列研究,在转诊中心2000至2023年开展。
  • 连续纳入巨大嗜铬细胞瘤患者,并按1:6比例随机选择非巨大嗜铬细胞瘤患者作为参照组。
  • 共828例嗜铬细胞瘤患者,其中31例(3.7%)为巨大嗜铬细胞瘤(中位大小12 cm,四分位距10.0-13.5 cm);参照组186例(中位大小4 cm,四分位距2.9-5.0 cm)。

主要发现

  • 巨大嗜铬细胞瘤患者儿茶酚胺过量症状中位数2 vs 参照组1(P = .04)。
  • 巨大嗜铬细胞瘤患者严重儿茶酚胺过量患病率76% vs 参照组30%(P < .0001)。
  • 巨大嗜铬细胞瘤患者肾上腺切除术实施率94% vs 参照组100%。
  • 巨大嗜铬细胞瘤患者围术期并发症率31% vs 参照组10%(P = .004)。
  • 中位随访3年期间,巨大嗜铬细胞瘤患者转移率45% vs 参照组4%(P < .0001);疾病特异性死亡率7% vs 参照组0%(P = .02)。

关键数值与推荐

  • 巨大嗜铬细胞瘤定义为大小10 cm或以上。
  • 术前α-肾上腺素能阻滞剂使用率89%;metyrosine(美替洛氨酸)用于14例(7%)患者,主要在巨大嗜铬细胞瘤患者中(26% vs 3%;P < .0001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Data on giant pheochromocytomas (PHEOs), defined based on size 10 cm or greater, are scarce. OBJECTIVE: This work aimed to compare presentation, management, and outcomes of patients with giant vs non-giant PHEOs. METHODS: A retrospective cohort study was conducted in a referral center from 2000 to 2023. Consecutive patients with giant PHEOs and randomly chosen patients with non-giant PHEO (referents) were studied at a 1:6 ratio. Outcomes included perioperative complications, metastases, and mortality. RESULTS: Of 828 patients with PHEOs, 31 (3.7%) had giant PHEO (median size 12 cm, interquartile range [IQR] 10.0-13.5 cm). In comparison to referents (n = 186, median size 4 cm, IQR, 2.9-5.0 cm), patients with giant PHEO had more symptoms of catecholamine excess (median of 2 vs 1; P = .04) and presented with a higher prevalence of severe catecholamine excess (76% vs 30%; P < .0001). Adrenalectomy was performed in 94% of patients with giant PHEOs and 100% of referents. In addition to preoperative α-adrenergic blockade (89%), metyrosine was used in 14 (7%) patients, mostly in patients with giant PHEOs (26% vs 3%; P < .0001). Patients with giant PHEOs had a higher perioperative complication rate (31% vs 10%; P = .004). During a median follow-up of 3 years, metastases developed at a higher rate in patients with giant PHEOs (45% vs 4% in referents; P < .0001). Disease-specific mortality was 7% in patients with giant PHEOs and 0% in referents (P = .02). CONCLUSION: Patients with giant PHEOs compared to referents were more symptomatic, had a higher degree of catecholamine excess, and had a higher rate of perioperative complications. Almost half of patients with giant PHEOs developed metastases, warranting close follow-up.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bahrani Fard B, Nikravangolsefid N, Maroun JW, et al. Presentation, Management, and Outcomes of Patients With Giant Pheochromocytoma. J Clin Endocrinol Metab. 2025. PMID: 39230590. doi:10.1210/clinem/dgae612

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。